Genomic Testing in the NCI-MATCH Cancer Trial
Tumor gene testing by a designated lab is the only pathway for patients to enroll in the NCI-MATCH precision medicine cancer trial.
To find patients who may be eligible, several commercial and academic laboratories are permitted by the National Cancer Institute to identify and refer potentially eligible patients to the trial. These referrals are based upon each lab’s standard tumor gene tests ordered by physicians at participating trial sites to guide clinical care for their patients.NCI-MATCH Locations
The laboratory referral process applies to any cancer patient who gets tumor gene testing at a cancer center or community hospital that is participating in the trial. NCI-MATCH is open and enrolling patients at nearly 1100 clinical sites in every state, the District of Columbia, and Puerto Rico.
Genomic Testing and the Laboratory Referral Process
Following are the basic steps:
- The process begins after a physician at a participating trial site orders routine genomic sequencing from one of the designated commercial labs (listed below) to guide clinical care for his or her patient
- The designated lab looks for tumor gene abnormalities being studied in NCI-MATCH as part of its standard testing procedure
- If the patient matches to the trial, the lab contacts the patient’s physician and provides a written referral letter or email
- If the patient and the physician decide to pursue NCI-MATCH as a treatment option, the physician uses the laboratory referral letter or email to register the patient into the trial for a screening assessment (Step 0). Cancer patients who enroll in the NCI-MATCH trial for a screening assessment will do so knowing in advance that they have a tumor gene abnormality matching one of the treatment arms in the trial and that they have a type of cancer that is allowed in that arm.
- Centrally, trial leaders review the referral. If they verify the referral, they formally assign the patient to the treatment arm and notify their physician.
- During the screening assessment (Step 0), the physician will evaluate the patient further for the specific eligibility requirements for the treatment arm to which they match
- Once enrolled in the treatment arm, the patient will be treated with a drug or drug combination that targets the molecular changes in their tumor for as long as their tumor shrinks or remains stable
Disclaimer: Personnel in clinical sites must review the master protocol for complete eligibility requirements and NOT rely upon this overview, which is not intended to be a comprehensive listing of inclusion and exclusion criteria.
Designated Commercial Laboratories
Name | Learn More | Contact |
Ashion Analytics, LLC
Joined 12/18/2019 |
Visit website | Inquire via email |
Caris Life Sciences®Â
Joined 06/23/2017 |
Visit website | Inquire via email |
CellNetix Pathology and Laboratories
Joined 02/13/2019 |
Visit website | Inquire via email |
Foundation Medicine, Inc.
Joined 05/11/2017 |
Visit website | Inquire via email |
GenPath (BioReference Laboratories, Inc.)
Joined 08/03/2018 |
Visit website | Inquire via email |
NeoGenomics Laboratories, Inc.
Joined 07/02/2018 |
Visit website | Inquire via email |
PathGroup (This site has suspended outreach to patients.) Joined 10/29/2018 |
Visit website | Inquire via email |
Quest Diagnostics Inc.
Joined 05/20/2019 |
Visit website | Inquire via email |
Strata Oncology, Inc.
Joined 08/03/2018 |
Visit website | Inquire via email |
Tempus Labs, Inc.
Joined 07/16/2018 |
Visit website | Inquire via email |
The Jackson Laboratory
Joined 01/10/2019 |
Visit website | Inquire via email |
Designated Academic Laboratories
Name | Joined |
Augusta University – Georgia Esoteric & Molecular Diagnostic Laboratory | 10/15/2018 |
Brigham and Women’s Hospital – Center for Advanced Molecular Diagnostics | 04/17/2019 |
Cedars-Sinai Medical Center – Molecular Pathology Laboratory | 02/13/2019 |
City of Hope National Medical Center – Clinical Molecular Diagnostics Laboratory | 11/02/2018 |
Columbia University – Laboratory of Personalized Genomic Medicine in the Department of Pathology and Cell Biology | 07/25/2018 |
Johns Hopkins Genomics | 01/29/2019 |
Massachusetts General Hospital – Center for Integrated Diagnostics | 07/25/2018 |
MD Anderson Cancer Center | 05/11/2017 |
Memorial Sloan Kettering Cancer Center | 08/03/2017 |
Molecular Characterization Laboratory at the Frederick National Laboratory for Cancer Research | 04/16/2019 |
National Cancer Institute – Laboratory of Pathology | 07/03/2019 |
Stanford Health Care – Molecular Genetic Pathology Laboratory | 02/25/2019 |
University of Chicago – Clinical Genomics Laboratory (This site has suspended outreach to patients.) |
10/05/2018 |
University of Colorado – Colorado Molecular Correlates Laboratory | 11/19/2018 |
University of Michigan – Michigan Medicine Molecular Diagnostics Laboratory | 10/19/2018 |
University of Washington – Genetics and Solid Tumor Laboratory | 09/16/2019 |
Weill Cornell Medicine – Clinical Genomics Laboratory | 08/03/2018 |
Yale University – Yale Tumor Profiling Laboratory | 06/20/2018 |
Â

Notes:
- This study entry process intends for participating NCI-MATCH trial sites to order testing from the designated commercial labs
- Patients and physicians may send emails directly to the designated commercial labs to request a review of a genomic test or seek general information--there is no need to contact the NCI or ECOG-ACRIN
- Generally, the designated academic labs, which are located in cancer centers, identify potential trial candidates from their own patient populations